Chronic hepatitis B virus infection in Eastern Ethiopia: Clinical characteristics and determinants of cirrhosis

被引:4
作者
Ismael, Nejib Y. [1 ]
Usmael, Semir A. [1 ]
Belay, Nega B. [2 ,3 ]
Mekonen, Hailemichael Desalegn [4 ,5 ]
Johannessen, Asgeir [3 ,5 ,6 ]
Orlien, Stian M. S. [3 ,5 ,7 ]
机构
[1] Haramaya Univ, Coll Hlth & Med Sci, Dept Internal Med, Jinella St, Harar 252, Ethiopia
[2] Addis Ababa Univ, Aklilu Lemma Inst Pathobiol, Addis Ababa 1000, Ethiopia
[3] Oslo Univ Hosp, Reg Ctr Imported & Trop Dis, N-0424 Oslo, Ulleval, Norway
[4] St Pauls Hosp Millennium Med Coll, Gastroenterol & Hepatol Unit, Internal Med, Addis Ababa 1000, Ethiopia
[5] Vestfold Hosp Trust, Dept Infect Dis, N-3103 Tonsberg, Norway
[6] Univ Oslo, Inst Clin Med, N-0318 Oslo, Norway
[7] Univ Oslo, Dept Pediat, N-0450 Oslo, Ulleval, Norway
关键词
Chronic hepatitis B; Cirrhosis; Cohort study; Resource-limited settings; Sub-Saharan Africa; TENOFOVIR DISOPROXIL FUMARATE; SIMPLE NONINVASIVE INDEX; KHAT CATHA-EDULIS; HEPATOCELLULAR-CARCINOMA; E-ANTIGEN; SIGNIFICANT FIBROSIS; DISEASE PROGRESSION; SPECIAL EMPHASIS; NATURAL-HISTORY; LIVER-CIRRHOSIS;
D O I
10.4254/wjh.v16.i7.995
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Chronic hepatitis B (CHB) virus infection is a major cause of liver-associated morbidity and mortality, particularly in low-income countries. A better understanding of the epidemiological, clinical, and virological characteristics of CHB will guide appropriate treatment strategies and improve the control and management of CHB in Ethiopia. AIM To investigate the characteristics of CHB in Eastern Ethiopia and assess the efficacy and safety of antiviral treatment. METHODS This cohort study included 193 adults who were human immunodeficiency virus-negative with CHB between June 2016 and December 2019. Baseline assessments included chemistry, serologic, and viral markers. chi 2 tests, Mann-Whitney U tests, and logistic regression analyses were used to identify the determinants of cirrhosis. Tenofovir disoproxil fumarate (TDF) was initiated using treatment criteria from the Ethiopian CHB pilot program. RESULTS A total of 132 patients (68.4%) were men, with a median age of 30 years [interquartile range (IQR): 24-38]. At enrollment, 60 (31.1%) patients had cirrhosis, of whom 35 (58.3%) had decompensated cirrhosis. Khat use, hepatitis B envelope antigen positivity, and a high viral load were independently associated with cirrhosis. Additionally, 66 patients (33.4%) fulfilled the treatment criteria and 59 (30.6%) started TDF. Among 29 patients who completed 24 months of treatment, the median aspartate aminotransferase to platelet ratio index declined from 1.54 (IQR: 0.66-2.91) to 1.10 (IQR: 0.75-2.53) (P = 0.002), and viral suppression was achieved in 80.9% and 100% of patients after 12 months and 24 months of treatment, respectively. Among the treated patients, 12 (20.3%) died within the first 6 months of treatment, of whom 8 had decompensated cirrhosis. CONCLUSION This study highlights the high prevalence of cirrhosis, initial mortality, and the efficacy of TDF treatment. Scaling up measures to prevent and control CHB infections in Ethiopia is crucial.
引用
收藏
页码:995 / 1008
页数:15
相关论文
共 61 条
[41]   Khat chewing increases the risk for developing chronic liver disease: A hospital-based case-control study [J].
Orlien, Stian Magnus Staurung ;
Sandven, Irene ;
Berhe, Nega Belay ;
Ismael, Nejib Yusuf ;
Ahmed, Tekabe Abdosh ;
Stene-Johansen, Kathrine ;
Gundersen, Svein Gunnar ;
Morgan, Marsha Yvonne ;
Johannessen, Asgeir .
HEPATOLOGY, 2018, 68 (01) :248-257
[42]   Unexplained chronic liver disease in Ethiopia: a cross-sectional study [J].
Orlien, Stian Magnus Staurung ;
Ismael, Nejib Yusuf ;
Ahmed, Tekabe Abdosh ;
Berhe, Nega ;
Lauritzen, Trine ;
Roald, Borghild ;
Goldin, Robert David ;
Stene-Johansen, Kathrine ;
Dyrhol-Riise, Anne Margarita ;
Gundersen, Svein Gunnar ;
Morgan, Marsha Yvonne ;
Johannessen, Asgeir .
BMC GASTROENTEROLOGY, 2018, 18
[43]   Liver disease and cirrhosis because of Khat chewing in UK Somali men: a case series [J].
Peevers, Camilla G. ;
Moorghen, Morgan ;
Collins, Peter L. ;
Gordon, Fiona H. ;
McCune, C. Anne .
LIVER INTERNATIONAL, 2010, 30 (08) :1242-1243
[44]   First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice [J].
Pol, S. ;
Lampertico, P. .
JOURNAL OF VIRAL HEPATITIS, 2012, 19 (06) :377-386
[45]  
Ramrez MenaA., 2022, Viruses, V14
[46]   SURVIVAL AND PROGNOSTIC FACTORS IN 366 PATIENTS WITH COMPENSATED CIRRHOSIS TYPE-B - A MULTICENTER STUDY [J].
REALDI, G ;
FATTOVICH, G ;
HADZIYANNIS, S ;
SCHALM, SW ;
ALMASIO, P ;
SANCHEZTAPIAS, J ;
CHRISTENSEN, E ;
GIUSTINA, G ;
NOVENTA, F .
JOURNAL OF HEPATOLOGY, 1994, 21 (04) :656-666
[47]   Hepatitis B Virus Kinetics under Antiviral Therapy Sheds Light on Differences in Hepatitis B e Antigen Positive and Negative Infections [J].
Ribeiro, Ruy M. ;
Germanidis, Georgios ;
Powers, Kimberly A. ;
Pellegrin, Bertrand ;
Nikolaidis, Paul ;
Perelson, Alan S. ;
Pawlotsky, Jean-Michel .
JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (09) :1309-1318
[48]   Khat (Catha Edulis) as a possible cause of autoimmune hepatitis [J].
Riyaz, Shahzad ;
Imran, Mohammad ;
Gleeson, Dermot ;
Karajeh, Mohammed A. .
WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (03) :150-154
[49]   A cross sectional study of HBeAg negative chronic hepatitis B virus infection in Cape Town, South Africa [J].
Roos, R. A. N. ;
Sonderup, M. W. ;
Smuts, H. ;
Gogela, N. ;
Setshedi, M. ;
Hairwadzi, H. N. ;
Spearman, C. W. .
JOURNAL OF VIRAL HEPATITIS, 2015, 22 :53-54
[50]  
Schiff ER., 2007, Schiff's diseases of the liver, V10th, P258